These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20939447)

  • 1. Cancer risk in diabetic patients treated with insulin glargine?
    Prescrire Int; 2010 Aug; 19(108):162-3. PubMed ID: 20939447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs.
    McFarland MS; Cripps R
    Pharmacotherapy; 2010 Nov; 30(11):1159-78. PubMed ID: 20973689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diabetes, insulin, insulin analogues, and cancer].
    Müssig K; Staiger H; Kantartzis K; Fritsche A; Kanz L; Häring HU
    Dtsch Med Wochenschr; 2010 May; 135(18):924-9. PubMed ID: 20425680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin glargine: a long-acting insulin for diabetes mellitus.
    Garces K
    Issues Emerg Health Technol; 2003 Nov; (52):1-4. PubMed ID: 14626260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.
    Edwards KL; Riche DM; Stroup JS; Goldman-Levine JD; Padiyara RS; Cross LB; Kane MP
    Pharmacotherapy; 2010 Sep; 30(9):955-65. PubMed ID: 20795850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin glargine for type 2 diabetes.
    Hemraj F; Garces K
    Issues Emerg Health Technol; 2004 Aug; (59):1-4. PubMed ID: 15311441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
    Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
    Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.
    Baur DM; Klotsche J; Hamnvik OP; Sievers C; Pieper L; Wittchen HU; Stalla GK; Schmid RM; Kales SN; Mantzoros CS
    Metabolism; 2011 Oct; 60(10):1363-71. PubMed ID: 21081242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin glargine (Lantus) and cancer risk.
    Med Lett Drugs Ther; 2009 Aug; 51(1319):67-8. PubMed ID: 19696708
    [No Abstract]   [Full Text] [Related]  

  • 12. Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes.
    Le Roith D
    Diabetes Metab Res Rev; 2007 Nov; 23(8):593-9. PubMed ID: 17922476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin.
    Juhaeri J; Gao S; Dai WS
    Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):497-503. PubMed ID: 19326365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin.
    Davis MD; Beck RW; Home PD; Sandow J; Ferris FL
    Exp Clin Endocrinol Diabetes; 2007 Apr; 115(4):240-3. PubMed ID: 17479440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on the long-acting insulin analogue glargine.
    Thisted H; Johnsen SP; Rungby J
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):1-11. PubMed ID: 16867163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue.
    Yki-Järvinen H
    Eur J Clin Invest; 2004 Jun; 34(6):410-6. PubMed ID: 15200492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with insulin glargine does not suppress serum IGF-1.
    Slawik M; Schories M; Busse Grawitz A; Reincke M; Petersen KG
    Diabet Med; 2006 Jul; 23(7):814-7. PubMed ID: 16842489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells.
    Mayer D; Chantelau E
    Arch Physiol Biochem; 2010 May; 116(2):73-8. PubMed ID: 20199195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
    Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
    Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.